Digest Network How does it work
Network
/
Society
Sa
Not verified

Sanofi - Aventis Groupe

What we write about

Foreign PolicyPharmaceuticals

48 Press releases

View all press releases
27/09/2024
Pharmaceuticals
Foreign Policy
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
27/09/2024
Pharmaceuticals
Foreign Policy
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
27/09/2024
Pharmaceuticals
Foreign Policy
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
27/09/2024
Pharmaceuticals
Foreign Policy
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
25/09/2024
Pharmaceuticals
Foreign Policy
Communiqué de presse : Mise en ligne du document «Q3 2024 Aide mémoire »
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
25/09/2024
Pharmaceuticals
Foreign Policy
Press Release: Availability of the Q3 2024 Aide mémoire
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
20/09/2024
Pharmaceuticals
Foreign Policy
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
20/09/2024
Pharmaceuticals
Foreign Policy
Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
20/09/2024
Pharmaceuticals
Foreign Policy
Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois  
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0
20/09/2024
Pharmaceuticals
Foreign Policy
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Source
Sanofi - Aventis Groupe
Issuer
GLOBENEWSWIRE
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0